ITCI - Intra-Cellular Therapies, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
20.45
+0.05 (+0.25%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close20.40
Open20.38
Bid16.15 x 900
Ask23.00 x 800
Day's Range20.28 - 20.77
52 Week Range10.25 - 25.82
Volume301,718
Avg. Volume346,625
Market Cap1.119B
Beta0.95
PE Ratio (TTM)N/A
EPS (TTM)-2.17
Earnings DateAug 3, 2017 - Aug 7, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est29.40
Trade prices are not sourced from all markets
  • ACCESSWIRE2 days ago

    Complimentary Technical Snapshots on Intercept Pharma and Three More Biotech Stocks

    LONDON, UK / ACCESSWIRE / July 16, 2018 / If you want a free Stock Review on ICPT sign up now at www.wallstequities.com/registration. Biotech firms differ from conventional drug makers in that they utilize natural ingredients, as opposed to synthetic ones.

  • GlobeNewswirelast month

    Intra-Cellular Therapies Initiates Rolling Submission of New Drug Application for Lumateperone for Treatment of Schizophrenia

    Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced the initiation of a rolling submission of its New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for lumateperone for the treatment of schizophrenia. The Company plans to complete this NDA submission in mid-2018. In 2017 the FDA granted Fast Track designation for lumateperone for the treatment of schizophrenia.

  • GlobeNewswire2 months ago

    Intra-Cellular Therapies Presents Data on Symptom Improvement by Lumateperone on Negative Symptoms, Depression, and Social Function in Patients with Schizophrenia at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

    Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, announced presentations on lumateperone at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting in Miami, Florida May 29-June 1, 2018. One of the Company’s presentations at ASCP focused on the effect of lumateperone on a specific domain of negative symptoms of schizophrenia known to correlate with social function.

  • GlobeNewswire2 months ago

    Intra-Cellular Therapies to Present at the Jefferies 2018 Global Healthcare Conference

    Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system ("CNS") disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the Jefferies 2018 Global Healthcare Conference in New York, NY. The live and archived webcast can be accessed under "Press Releases & Events" in the Investor Relations section of the Company's website at www.intracellulartherapies.com. Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease.

  • GlobeNewswire2 months ago

    Intra-Cellular Therapies Announces Presentations on Lumateperone at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

    Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, announced poster presentations at the upcoming American Society of Clinical Psychopharmacology (ASCP) Annual Meeting in Miami, Florida May 29-June 1, 2018. A poster presentation (W54) entitled, “Lumateperone Improves Negative Symptoms Related to Emotional Experience (Avolition) in Patients with Schizophrenia” is being presented Wednesday, May 30, 2018, 11:15 am - 1:00 pm ET. This poster will be presented by Dr. Philip D. Harvey, Leonard M. Miller Professor of Psychiatry and Behavioral Sciences at the University of Miami Miller School of Medicine.

  • GlobeNewswire2 months ago

    New Research: Key Drivers of Growth for CSW Industrials, Cavco Industries, Intra-Cellular Therapies, Atrion, QAD, and A V Homes — Factors of Influence, Major Initiatives and Sustained Production

    NEW YORK, May 24, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of CSW ...

  • ACCESSWIRE2 months ago

    Free Stock Performance Review on Array BioPharma and Three More Biotech Industry

    Losses were broad based as all sectors finished the trading session in red. WallStEquities.com has initiated research reports on the following Biotechnology stocks: Intra-Cellular Therapies Inc. (NASDAQ: ITCI), Argos Therapeutics Inc. (NASDAQ: ARGS), Array BioPharma Inc. (NASDAQ: ARRY), and Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH).

  • GlobeNewswire2 months ago

    Intra-Cellular Therapies to Present at the Bank of America Merrill Lynch 2018 Health Care Conference

    Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system ("CNS") disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the Bank of America Merrill Lynch 2018 Health Care Conference in Las Vegas, NV. The live and archived webcast can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at www.intracellulartherapies.com. Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease.

  • GlobeNewswire2 months ago

    Intra-Cellular Therapies Announces Presentations on Lumateperone at Two Upcoming Medical Conferences

    Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, announced presentations on lumateperone at the 2018 American Psychiatric Association (APA) Annual Meeting in New York, May 5-9, 2018, and at the Society of Biological Psychiatry (SOBP) Annual Meeting in New York, May 10-12, 2018. A poster presentation (P5-178) entitled “Lumateperone (ITI-007) for the Treatment of Schizophrenia: Overview of Placebo-Controlled Clinical Trials and an Open-Label Safety Switching Study” is being presented Monday, May 7, 2018, 10:00 am - 12:00 pm ET during Poster Session 5.

  • Associated Press2 months ago

    Intra-Cellular: 1Q Earnings Snapshot

    The New York-based company said it had a loss of 65 cents per share. The results matched Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was also for ...

  • GlobeNewswire2 months ago

    Intra-Cellular Therapies Reports First Quarter 2018 Financial Results and Provides Corporate Update

    Research and development (R&D) expenses for the first quarter of 2018 were $30.7 million, compared to $21.5 million for the first quarter of 2017. In the first quarter of 2017, outside costs were incurred for the Phase 3 clinical trials of lumateperone in patients with bipolar depression and dementia and other lumateperone related trials.

  • GlobeNewswire3 months ago

    Intra-Cellular Therapies Presents Data on ITI-214 at the 2018 American Academy of Neurology Annual Meeting

    Phase 1/2 clinical trial in patients with Parkinson's disease (PD) expanded to add additional cohort. NEW YORK, April 26, 2018 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, announced it is presenting a poster on ITI-214, its novel selective phosphodiesterase 1 (PDE1) inhibitor, at the 2018 American Academy of Neurology Annual Meeting being held in Los Angeles, California April 21-27, 2018. The poster presentation (P5-067) entitled “ITI-214, A Novel Phosphodiesterase Type I Inhibitor, for the Treatment of Motor and Non-motor Symptoms of Parkinson's Disease” is being presented today Thursday April 26, 2018, 5:30 pm — 7:00 pm during Poster Session 5.

  • Here's Why Alkermes plc and Intra-Cellular Therapies, Inc. Are Crashing Today
    Motley Fool4 months ago

    Here's Why Alkermes plc and Intra-Cellular Therapies, Inc. Are Crashing Today

    Bummer regulatory news causes traders to flee from these two biopharmas. Here's what investors need to know.

  • ACCESSWIRE4 months ago

    Wired News – FDA Approved Intra-Cellular’s Rolling NDA Submission for Lumateperone for Schizophrenia

    Stock Monitor: Concordia Intl. Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 15, 2018 / Active-Investors.com has just released a free research report on Intra-Cellular Therapies, Inc. (NASDAQ: ...

  • Thomson Reuters StreetEvents5 months ago

    Edited Transcript of ITCI earnings conference call or presentation 1-Mar-18 1:30pm GMT

    Q4 2017 Intra-Cellular Therapies Inc Earnings Call

  • Associated Press5 months ago

    Intra-Cellular reports 4Q loss

    The New York-based company said it had a loss of 56 cents per share. The results did not meet Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for ...

  • ACCESSWIRE5 months ago

    Intra-Cellular Therapies, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 1, 2018 / Intra-Cellular Therapies, Inc. (NASDAQ: ITCI ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 1, 2018, at 8:30 AM Eastern ...